Rachel Zolot Schwartz

Life sciences enthusiast, Business Development Leader. Opinions are my own.

[UT MD Anderson @UTMDAnderson]

Early findings from a first-in-human trial of VLS-1488, an oral KIF18A inhibitor, show promising anti-tumor activity in heavily treated ovarian cancer. No dose-limiting toxicities were observed. Presented by Dr. Ecaterina Dumbrava at #ASCO25. #EndCancer

[Latest News from Business Wire @NewsFromBW]

Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting https://t.co/NqmzxTQewn

[Endpoints News @endpts]

Volastra reveals first human data of its oral drug to treat solid tumors.
https://t.co/xKwOrFYbeh

[Bill Ackman @BillAckman]

An extremely thoughtful letter from Marc Rowan to the University of Pennsylvania community and the world.

https://t.co/DMpxOGPzpO

[Rachel Zolot Schwartz @RachelZolot]

So excited for Volastra Therapeutics and to be part of the next chapter in our journey to develop drugs to cure cancer #oncology #biotech #dealmaking

[FierceBiotech @FierceBiotech]

Cancer-focused Volastra is buying its way into the clinic, adding a phase 1 asset from Amgen and $60 million in financing.
https://t.co/gZhuosHANE

[FierceBiotech @FierceBiotech]

Cancer-focused Volastra is buying its way into the clinic, adding a phase 1 asset from Amgen and $60 million in financing.
https://t.co/gZhuosHANE

[Rachel Zolot Schwartz @RachelZolot]

Last week I had the pleasure of participating on a lively panel at the @FierceBiotech Summit on innovative deal making in #biotech with @INasrullah64 @AbbasRKazimi and Sarah Hogan

[Volastra Therapeutics @VolastraTx]

Volastra’s management team accepted the #Fierce15 award on behalf of the team at the #FierceBiotechSummit last week. We’re proud to be recognized among such a distinguished group of peers, and we are grateful for all the hard work that made this possible.
#biotech @FierceBiotech

[Fierce Life Sciences Events @LifeSciEvents]

Join us in welcoming Rachel Zolot Schwartz, MBA, VP, Head of Business Development and Commercial of @VolastraTx to the esteemed speaking faculty of the Fierce Biotech Summit on Sept. 19-20 in Boston, MA! Join Rachel by registering now at: https://t.co/AxHs3wpu3V

[Rachel Zolot Schwartz @RachelZolot]

Excited to chair the Business Development Committee @Jaguar_Health and continue to optimize the global development & commercialization of crofelemer #lifesciences #businessdevelopment #plantbasedmedicines

[Jaguar Health (NASDAQ: JAGX) @Jaguar_Health]

Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions https://t.co/iU2Ext2Ype

[Rachel Zolot Schwartz @RachelZolot]

What a fantastic panel at #RESI on trends in deal making with pharma and considerations when partnering with companies at different stages. Thanks to the panelists for their insightful perspectives #biotech #pharma #partnering

[Volastra Therapeutics @VolastraTx]

#ICYMI - Rachel Zolot Schwartz, VP, Head of Business Development & Commercial, moderated yesterday’s Digital #RESI “Beyond Big Pharma” panel. Thanks @LSciNation for giving #lifescience #investors & industry the opportunity to discuss #businessdevelopment & #partnering!

[Volastra Therapeutics @VolastraTx]

ICYMI: Earlier this week we announced an exciting collaboration with @BMSnews to leverage our proprietary CINtech platform to discover and develop new cancer drug candidates. Learn more in this article from @endpts: https://t.co/diVtNKjfZo

[Volastra Therapeutics @VolastraTx]

Curious what our new partnership with Bristol Myers Squibb entails? Learn more about our latest collaboration and how it came about in @FierceBiotech: https://t.co/kyfLbJniHa

[Volastra Therapeutics @VolastraTx]

We're thrilled to announce our #drugdiscovery collaboration with @bmsnews focused on leveraging our unique CINtech platform to identify CIN-related, synthetically lethal targets for the development of effective CIN-targeted #cancer therapies. Learn more: https://t.co/y0eou1jY9O

[Sara Nayeem @SaraNayeem]

You’re more than a number – whether that’s your stock price, a clinical trial p value, a quarterly sales #, or the IRR on capital you’ve returned. This truth can be heartening when facing a moment of deep disappointment, even if it’s somewhat collective. The biotech...1/6

[Volastra Therapeutics @VolastraTx]

What does a lab that incorporates both #experimental & #computational tools look like? See for yourself!

#biotech #NYCbiotech #cancerresearch

[Volastra Therapeutics @VolastraTx]

We announced a number of key hires across our translational, data science and business development functions as well as key appointments within our scientific leadership team in biology, immunology and chemistry to accelerate our goal of stopping #cancer: https://t.co/jZ0OL2SvMg

[Rachel Zolot Schwartz @RachelZolot]

@_MrsDLuciano @MrsCONeill1 @Mr_Weill Omg this melts my heart #heathcote

[Rachel Zolot Schwartz @RachelZolot]

Best time hanging at the @VolastraTx lab with one of my oldest friends @alexanderchiang from my days @TrinityLifeSci #oncology #biotech #westharlem

[Volastra Therapeutics @VolastraTx]

We’re looking for a stellar computational biologist to join our efforts in identifying and targeting #chromosomalinstability. Up for the challenge?

If so, check out our open positions: https://t.co/ziLZeplsyi #biotechjobs